Mirum Pharmaceuticals, Inc. MIRM Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Mirum Pharmaceuticals, Inc. (MIRM) reported total cash, cash equivalents, and restricted cash (inclusive) of $326.64M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) increased by 53.9% year-over-year, from $212.25M to $326.64M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a 32.6% compound annual growth rate (CAGR), from $128M to $298.17M.